Newly onset cytopenias not always indicate a relapsing AML after allogeneic HSCT, a case of non-destructive post transplant lymphoproliferative disorder
![Thumbnail](/xmlui/bitstream/handle/20.500.12511/10965/Yi%c4%9fit%20Kaya-S%c3%bcreyya-2023.pdf.jpg?sequence=4&isAllowed=y)
View/ Open
Access
info:eu-repo/semantics/openAccessAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttps://creativecommons.org/licenses/by-nc-nd/4.0/Date
2023Metadata
Show full item recordCitation
Yiğit Kaya, S., Aşkın, A. E., Bektaş, Ş., Çakır, A. ve Gökmen Sevindik, Ö. (2023). Newly onset cytopenias not always indicate a relapsing AML after allogeneic HSCT, a case of non-destructive post transplant lymphoproliferative disorder. Leukemia Research Reports, 19. https://doi.org/10.1016/j.lrr.2023.100369Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains an effective option for the treatment of intermediate and high-risk Acute myeloid leukemia (AML). Post-transplant lymphoproliferative disorder (PTLD) is related to the intensity of post-transplant immunosuppression. Although Epstein-Barr virus (EBV) seropositivity and reactivation can be a major risk factor for PTLD. A few PTLDs could be EBV negative. There are a very limited number of PTLD cases following HSCT in patients with AML. We present a differential diagnosis of cytopenias after allo-HSCT. This is the first report of an AML patient developing bone marrow EBV-negative PTLD relatively late in their post-transplant course.
xmlui.dri2xhtml.METS-1.0.item-scopusquality
Q3Source
Leukemia Research ReportsVolume
19Collections
- Makale Koleksiyonu [3777]
- PubMed İndeksli Yayınlar Koleksiyonu [4230]
- Scopus İndeksli Yayınlar Koleksiyonu [6574]
- WoS İndeksli Yayınlar Koleksiyonu [6631]